Breadcrumb

Ravi A. Madan MD

Ravi A. Madan, M.D.

  • Center for Cancer Research
  • National Cancer Institute

RESEARCH SUMMARY

Dr. Madan's clinical research is focused on immune stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. Currently, Dr. Madan is investigating the potential of immunocytokines in prostate cancer.

In addition, Dr. Madan is also evaluating treatments in patients with early recurrence of prostate cancer after definitive surgery or radiation (e.g. biochemical recurrence).  These clinical trials include interventions such as immunotherapy, radiopharmaceuticals, and anti- androgens, but spare the use of testosterone lowering therapy (i.e. androgen deprivation therapy). Dr. Madan is also the program director of CCR's Physician-Scientist Early Investigator Program.

Areas of Expertise

1) prostate cancer 2) biochemically recurrent prostate cancer 3) metastatic prostate cancer 4) immunotherapy  5) immunocytokines 6) therapeutic cancer vaccines

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Publications

Selected Recent Publications

With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer

Ravi A Madan, Esther Mena, Liza Lindenberg, Peter L Choyke
Journal of Clinical Oncology. 2022.
Full-Text Article
[ Journal Article ]

The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer

Adam M Kase, Winston Tan, John A Copland 3rd, Hancheng Cai, Ephraim E Parent, Ravi A Madan
Cancers. 2022.
Full-Text Article

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

Ravi A Madan, Fatima Karzai, Renee N Donahue, Munjid Al-Harthy, Marijo Bilusic, et al.
Journal of Immunotherapy for Cancer. 2021.

Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy

Scott Wilkinson, Huihui Ye, Fatima Karzai, Stephanie A Harmon, Nicholas T Terrigino, David J VanderWeele, John R Bright, Rayann Atway, Shana Y Trostel, Nicole V Carrabba, Nichelle C Whitlock, Stephanie M Walker, Rosina T Lis, Houssein Abdul Sater, Brian J Capaldo, Ravi A Madan, James L Gulley, Guinevere Chun, Maria J Merino, Peter A Pinto, Daniela C Salles, Harsimar B Kaur, Tamara L Lotan, David J Venzon, Peter L Choyke, Baris Turkbey, William L Dahut, Adam G Sowalsky
Eur Urol. 21: 2021. [ Journal Article ]

Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations

Vincent Chau, Ravi A Madan, Marijo Bilusic, Helen Owens, Lisa M Cordes, Jennifer L Marte, James L Gulley, Jung-Min Lee, William L Dahut, Fatima Karzai
Clin Genitourin Cancer. 17: 2021. [ Journal Article ]

Job Vacancies

Position Degree Required Contact Name Contact Email
Clinical Research Physician - Clinical research, prostate cancer M.D. or equivalent Dr. Ravi Madan madanr@mail.nih.gov

Team

Special Volunteer
Philip Arlen, M.D.
Patient Care Coordinator (Contr.)
Carlos Diaz
Physician Assistant
Amy Hankin, PA-C, MMSc
Research Nurse
Elizabeth Lamping, R.N., B.S.N.
Research Nurse
Sheri McMahon, R.N., B.S.N.
Research Nurse
Helen Owens
Clinical Collaborator
Lee Pai-Scherf, M.D.
Patient Care Coordinator (Contr.)
Moniquea Smith
Clinical Collaborator
Marc Theoret, M.D.
Nurse Practitioner (Contr.)
Monique Williams, N.P.